Tumor neoantigens are fragments of mutated proteins that contain the mutation, and can be presented by major histocompatibility complex molecules on tumor cells, where they are surveyed by T cells. The rapid and sensitive identification of neoantigen-specific T cell populations from tumor tissues or blood has proven challenging. A microchip platform for the non-destructive identification of neoantigenspecific CD8+ T cells is described. The method utilizes a library of neoantigen/MHC tetramers linked to a magnetic nanoparticle via a DNA barcode. The neoantigen-specificity of the T cells is determined by decoding the barcode through sequential fluorescent microscopy reads. The captured T cells may be further characterized for function, or via matching the neoantigen-specificity with the T cell receptor gene. Tumor infiltrating lymphocytes and non-expanded peripheral blood mononuclear cells collected from melanoma patients at various time points across an anti-PD1 therapy regimen are shown to contain overlapping neoantigen-specific T cell populations.
Introduction:
Tumor neoantigens have been implicated as playing important roles in the recognition of cancer cells by the immune system Schumacher and Schreiber, 2015) and are candidate targets for personalized cancer vaccines. (Carreno et al., 2015; Gubin et al., 2014) Neoantigens (also called neoepitopes) are fragments of mutated proteins that contain the mutation, and can be presented in the cleft of Major Histocompatibility Complex (MHC) Class I molecules on the surfaces of cells within the tumor, where they are surveyed by CD8+ T cells. The tumor-specificity of neoantigens, coupled with the ability of neoantigen-specific T cells to specifically kill cancer cells (Lu et al., 2014; Robbins et al., 2013) , have made them increasingly important for cancer immunotherapy. Furthermore, T cell receptors (TCRs) that recognize specific neoantigens are candidates for TCR-engineered cell based therapies. (Stroncek et al., 2012) Putative neoantigens can be identified by tumor exome analysis, (Lu et al., 2014; Robbins et al., 2013; Rooij et al., 2013; Yadav et al., 2014) and then rank-ordered according to MHC binding strength (Fritsch et al., 2014; Nielsen et al., 2007) , as well as filtered by accounting for gene expression. However, finding which candidates actively promote T cell tumor recognition is challenging on several fronts. First, a patient tumor that has a mutation density of 10 per 1 million expressed DNA base pairs might have more than 100 putative neoantigens that exhibit a calculated binding constant (kd) to a given HLA genotype MHC of 500 nM or stronger. Further, any particular neoantigen-specific T cell population is likely to exist in low abundance. Additional challenges are associated with pairing neoantigens to their cognate TCRs.
Nevertheless, such interactions are the core of cancer immunotherapy, (Coulie et al., 2014) and so there has been significant effort towards meeting these challenges. One approach involves expressing the nucleotide sequences of the putative neoantigens within antigen-presenting target cells that are HLAgenotype matched with the patient, and then incubating those cells with tumor infiltrating lymphocytes (TILs) or T cells from peripheral blood mononuclear cells (PBMCs) to identify populations of T cells that are reactive against those neoantigens. (Linnemann et al., 2015; Robbins et al., 2013) This approach, while laborious, can identify the presence of neoantigen-specific T cell populations, but does not provide a quantitative enumeration of those populations. A second approach, reported by the Schumacher group, involves the use of MHC tetramers, each labeled with multiple fluorophores to enable colorimetric multiplexing in a flow cytometry-based detection scheme. (Andersen et al., 2012) This technique has been used for the analysis of T cell populations from in vitro expanded TILs and PBMCs. (Rizvi et al., 2015) A related mass cytometry variant, which uses mass labels in place of the fluorophores has also been reported, (Newell et al., 2013) , as has a DNA-labeled tetramer approach the combines flow cytometry with PCR amplification of the labels. (Bentzen et al., 2016) As discussed below, these flow cytometry methods have limitations when used to quantitate small populations of antigen-specific T cells from small biospecimens. This can be partially addressed by in vitro expansion of the T cells, but such expansion can significantly alter T cell population profiles. Further, expansion significantly extends the time required for the analysis. For a tumor with a high mutational burden, these methods typically identify a few neoantigenspecific CD8+ T cell populations for a given HLA genotype. A further measurement challenge is to match the neoantigen-specificity of a T cell with the TCR genes.
The TCR protein is a heterodimer composed of a variable α chain and a variable β chain, with the matched α/β chains defining the T cell antigen specificity. The (single cell) pairSEQ technique recently reported by Robins' group (Howie et al., 2015) provides an elegant approach for assembling the full TCR gene sequence from separate measurements of α and β chains from a population of T cells. However, this method does not establish the antigen specificity of that gene, and is likely challenging to employ when analyzing small populations of T cells with a variety of antigen specificities. In general, the dual challenge of identifying neoantigen-specific T cells and matching them with their cognate TCR genes increases in difficulty as abundance of the individual T cell populations drops.
Here, we report a method, which we call barcoded nanoparticle-nucleic acid cell sorting (barcoded NP-NACS), for the highly sensitive enumeration of neoantigen-specific T cell populations from TILs or nonexpanded PBMCs collected from cancer patients. Once paired with a neoantigen, the T cells may be further analyzed at the functional or genetic level.
Results

Capture of antigen-specific T cells using magnetic nanoparticles surface-coated with antigen/MHC tetramers
MHC tetramers coupled onto magnetic nanoparticle (NP) surfaces provide an excellent platform for sorting antigen-specific T cells, since the high loading of tetramers achievable on individual NPs builds upon the cooperative binding advantage that the tetramer scaffold itself provides. We tested this hypothesis by analyzing a sample of Jurkat T lymphocyte cells that were spiked with between 1 and 1000 NY-ESO TCR-specific Jurkats, within a constant cell count of 10,000. The NY-ESO antigen is a cancer testis antigen that has been targeted in various adoptive cell therapy trials (Rapoport et al., 2015; Robbins et al., 2011) . We compared the sensitivity of magnetic capture of the NP-tetramer labeled cells to what could be achieved using the multi-color flow cytometry staining scheme (Andersen et al., 2012) ( Figure 1 A,B ). This assay was also used to optimize the size of the NP. Smaller NPs, such as those below radius (r)=50 nm, require strong magnetic fields for cell enrichment. To achieve such fields, columns filled with steel beads are utilized to increase the magnetic field gradient to maximize separation efficiency. We found that such columns greatly reduced cell recovery when handling small (10 4 ) cell numbers. On the other hand, particles of r>1 micrometer tend to precipitate from solution due to gravity, and so are difficult to handle. NPs of r = 500 nm avoided both of these issues and so were selected. Each 500 nm NP presents 10 5 sites or more (see STAR Methods) for attaching the antigen-MHC tetramer.
The antigen-MHC constructs used for FC analysis and magnetic capture were identical (Fig 1A, B) . In both cases, they were assembled onto a streptavidin scaffold to form a tetramer. For flow cytometry analysis, the streptavidin was dye labeled with one of two fluorophores, following literature protocols (Andersen et al., 2012) . For magnetic capture, the tetramer scaffold utilized cysteine-modified streptavidin(SAC) (Ramachandiran et al., 2007) to facilitate site-specific incorporation of ssDNA linkers (Kwong et al., 2009 ) for connecting to the NP via DNA hybridization (see STAR Methods).
Flow cytometry analysis of the spiked samples was done using both tight (conservative) and loose gating schemes. (see STAR Methods and Supplementary Figure S1 .A). NY-ESO TCR specific Jurkat cells were identified as those cells that stained positive for both dyes. For the NP-tetramer detection, we used a Calcein AM fluorescent live cell stain so that when the captured cells were viewed on a hemocytometry chip, they could be counted using fluorescence microscopy (Fig S1.B) . Both flow cytometry gating schemes, as well as the NP-tetramer capture, yielded excellent linear performance for detecting the NY-ESO TCR-specific Jurkat cells over the full spiked range of 10 3 ( Figure S1 .C). For the flow cytometry method, when a loose gate was utilized to achieve maximum sensitivity for double-fluorescent positive NY-ESO Jurkat cells, some false-positives were counted. Thus, the numbers of cells detected was slightly above (103%) what was spiked. On the other hand, when a tight gate was utilized to minimize false positives, sensitivity for double-fluorescent positive NY-ESO Jurkat cells was sacrificed ( Fig. S1 . A), and 64% of the spiked cells were detected. A key finding was that over the extreme dilution range of 0-10 spiked cells, the NP-tetramer method yielded quantitatively superior performance ( Figure 1C ) to either of the FC gating schemes. The sensitivity of the flow cytometry was consistent with expectations from literature (Bentzen et al., 2016) . This data illustrates that 500 nm radius magnetic NPs, surface coated with antigen/MHC Class I tetramers, provide a highly sensitive method for the capture of antigen-specific CD8+
T cells that outperforms the gold standard FC method for very low abundance cells from small samples sizes (10 4 cells).
The barcoded NP-NACS library method for analysis of neoantigen-specific T cells
We modified the NP-tetramer capture approach to permit the parallel capture of multiple populations of antigen-specific CD8+ T cells collected from patient materials. To this end, we altered the process flow of Figure 1B in three ways, as illustrated in Figures 2A, B . First, we utilized the well-established method of conditional antigen exchange (Bakker et al., 2008; Celie et al., 2009) to enable the rapid construction of a library of antigen-MHC tetramers (see STAR Methods). Second, we expanded the DNA linker that connects the antigen/MHC complex to the magnetic NP to incorporate an ssDNA barcode. Third, we developed a microfluidic platform for isolating those individual T cells that are magnetically captured, so as to permit a fluorescence microscopy-based decoding of each barcoded T cell. The chemical process associated with barcode readout is demonstrated in supplementary figure S2. We used an ssDNA barcode designed with 3 positions, each of which have 3 possible sequences. For each position, the specific sequence is read using ssDNA oligomers labeled with one of 3 fluorophores. Only one of those oligomers will hybridize. For a full list of the ssDNA reagents and their corresponding barcode usage, refer to supplementary tables S1
and S2, respectively. Thus, the labeled cell will fluoresce red, green or yellow, depending upon the sequence at that position. Once a position is read, the fluorescent ssDNA oligomer is removed using a displacement ssDNA oligomer, and the next position is read. In this way, an n-color, m-position barcoded yields n m multiplexing capability. Figure 2C , as an example, lists the barcodes assigned to 26 neoantigens plus the MART-1 melanosomal antigen for patient #1. This decoding process is efficient (Supplementary figure S2 ), but requires that the captured cells be held in place as various solutions are introduced, flushed, etc. Because virtually all reagents used here will stick to dead cells, the cells must also remain viable throughout the capture and barcode readout process. We constructed an elastomer-based microfluidic chip designed with a series of microchambers, each of which contained 10 separate single cell traps ( Fig   2B, Supplementary figure S3) . Once a T cell is labeled with tetramer/DNA/NP constructs, the T cell is considered barcoded. We named the full approach of antigen-specific T cell labeling, capture and readout as barcoded nanoparticle nucleic acid cell sorting, or barcoded-NP NACS.
Analysis of tumor infiltrating lymphocytes from melanoma cancer patient biopsies
We used the above methods to analyze human CD8+ cells expanded from tumor infiltrating lymphocytes (TILs) collected from tumor biopsies of three patients with metastatic melanoma who were being treated with checkpoint inhibitor therapy at the time of biopsy (Supplementary Patient Information).
These patients were treated with the anti-PD-1 antibody pembrolizumab within a phase I trial. (Ribas et al., 2016 ) Therapy responses were mediated by tumor infiltrating CD8+ cells. (Tumeh et al., 2014) The response of patient #1 to the therapy is illustrated in the images of Figure 3A , and in the timeline of Figure   3B . The points at which various biospecimens were collected from patient #1 are also indicated in Fig 3B. For all 3 patients, a pre-treatment biopsy was analyzed for both the tumor exome and gene expression (see STAR Methods). In silico analysis was carried out to prepare rank-ordered lists of putative neoantigens for HLA-A*0201, with respect to MHC binding affinity (see STAR Methods, and Supplementary Tables S3-S8 ).
Those lists were unique for each patient and informed the construction of the barcoded NP-NACS libraries.
For patient #1 the tightest binding 50 putative neoantigens plus the MART-1 melanoma antigen were tested.
The list of Fig 2C includes the top 26 neoantigens from those 50. For neoantigen numbers 3, 5, 11, 26, 31, 34, 36, 37, 46 and 48, the corresponding transcripts for those proteins yielded zero mutation reads (Supplementary Table S6 ). Thus, these non-expressed neoantigens provided controls that spanned the sampled range of neoantigen/MHC binding affinities.
The barcoded NP-NACS library elements were combined and used to capture 4.5-5% of the CD8+ TILs. We also recorded a 0.5% non-selective capture, based upon testing the library against CD4+ T cells from the same TILs sample ( Supplementary Fig. S4 ). Two separate runs on different vials of expanded patient #1 TILs, were similarly analyzed and yielded the same seven neoantigen-specific T cell populations (plus MART-1 specific cells, which provided a positive control) ( Supplementary Fig. S5 ). All but very lowabundance populations (1 or 2 incidents per analysis) were detected in both assays. The most abundant population (1.2% of CD8+ cells) was specific for neoantigen #12. We further analyzed patient #1 TILS for specificities against neoantigens ranked 28-50 (kd values up to 500 nM). Two additional populations were detected (#'s 38 and 45). Figure 2B provides some of the single cell fluorescent readouts that were used to assign populations. Some traps will capture 2 cells (see Fig 2B trap #4) . Microscopic inspection will typically permit at least one of those cells to be distinguished for barcoding. Typically, we either get a high fidelity read or a nonsense read which we discard (see trap #8 in Fig 2B) . This lends a very low noise level to the approach. We defined detected neoantigen-specific T cell populations as those identified by 3 or more unambiguous reads, or detected in both analyses of patient #1 TILs. The summed analysis of patient #1 TILs is provided in Fig. 3C (top histogram).
For comparison, some biospecimens were analyzed using the serial hemocytometry approach of Figure 1B . Like barcoded NP-NACS, this approach is also highly efficient in the use of available cells.
Neoantigen-specific T cells are precipitated from a population of, for example, 10,000 CD8+ T cells, but that same population is then re-interrogated using the next NP-NACS library element. The method is particularly useful for analysis of non-expanded PBMCs, where neoantigen-specific T cell populations are particularly rare (see below). In such cases, it can be challenging to remove all of the unbound magnetic NPs while not also losing some of the barcoded cells. This removal is necessary for the fluorescent readout, since unbound NPs will interfere with the barcoded NP-NACs process. However, such unbound particles do not interfere with the hemocytometry approach (supplementary Fig S1.B) . To characterize the non- Fig. S6 ), indicating that no patient #1 library elements are of intrinsically low-selectivity.
Using the barcoded NP-NACS library for patient #2, serial analysis of that patient's TILs yielded a similar number of neoantigen-specific T cell populations as were found for patient #1. (Supplementary Fig. S7 ).
The above TILs analyses revealed a larger number of neoantigen-specific T cell populations than have been reported using multiplex flow cytometry analysis.
(1-4) We thus analyzed the expanded patient #1 TILs using the multiplex flow method. (Andersen et al., 2012) For that analysis, we prepared a 14-element tetramer library presenting putative neoantigens 1-8, 12, 14, 15, 19, 27 and MART-1 (8 of which were detected using barcoded NP-NACS) (see STAR Methods). When using loose gate to obtain maximum sensitivity, 7 different neo-antigens were detected. This is significantly higher than what was found from a control flow cytometry analysis of CD8+ T cells from a healthy donor ( Supplementary Fig. S8-S9 ). However, if a tight gate is utilized, only T cells specific to neoantigen #12 were detected in two and only two colors ( Supplementary Fig. S8 ). The abundance of neoantigen #12 specific T cells detected by flow cytometry vs barcoded NP-NACS, was different (4% versus 1.2%). This likely arises from the subset of CD8+ T cells analyzed by the two methods (see STAR Methods and Supplementary Fig S10) . In particular, all neoantigen #12-specific T cells identified using flow cytometry were from the subset of those cells that were CD8++.
For the vial that was expanded for flow cytometry analysis, this CD8++ population was 20% of the live, CD3+ cells. In the vial expanded for barcoded NP-NACS analysis, the corresponding percentage was 8%.
These results indicate that the sensitivity of the barcoded NP-NACS method, coupled with the selective identification of individual cells through the barcoding process, allows the detection of neoantigen-specific CD8+ T cell populations that are not detected using flow cytometry.
Barcoded NP-NACS for the analysis of non-expanded PBMCs
The sensitivity of the barcoded NP-NACS method prompted us to analyze peripheral blood from patient #1 and patient #3 ( Fig. 3 and Supplementary Figs . S11-S13). We did not expand these T cells in vitro, so as to avoid any accompanying population bias. We used the 49-element neoantigen library to interrogate patient #1 PBMCs collected at four time points. Two time points (Days 187 and 208, Fig 3A) were collected during therapy response while tumors were shrinking, and corresponded closely to the date of the tumor biopsy (Day 187) from which the TILs were collected. For those samples, the total abundance of detected neoantigen-specific T cell levels was well below those found in the TILs (1% of all CD8+ PBMCs vs 7% of all CD8+ TILs), but we positively detected several populations at levels of >5 cells per 10 4 CD8+ PBMCs.
Most PBMC populations coincided with those detected from the TILs, with two new populations (specific to neoantigens #15 and #33) identified. Analysis of PBMCs at Day 439, at the end of tumor regression, detected no such populations ( Supplementary Fig. S11 ). This last point emphasizes the selectivity of the method, and again indicates that none of the library elements were intrinsically low selectivity.
Day 41 PBMCs correspond to a time close to the biopsy from which the exome and transcriptome measurements were taken, but also during a period of pseudo-progression for patient #1 prior to response ( Fig 3A) . Analyzing PBMCs at this time point was pure discovery science, as we could not formulate a hypothesis for whether or not neoantigen-specific CD8+ T cell populations would be detected. In fact, we Table S6 ). Further, for the 10 neoantigens in the panel for which corresponding mRNA levels were measured to be zero, only the strong binding neoantigen #5 was associated with any detected populations (TILs and Day 41 PBMCs).
For patient #3, we used a 34-element neoantigen-MHC tetramer library (Supplemental Table S5 ) to analyze expanded TILs and non-expanded PBMCs. A baseline noise level was established by testing this library against a different patient's PBMCs ( Supplementary Fig S12) . Unlike patients #1 and #2, the patient #3 TILs were from a biopsy collected 29 days prior to start of therapy ( Supplementary Fig. S13A ). Patient #3 also had a very different response profile to anti-PD1 therapy. CD8+ cells from the TILs expanded very slowly compared to CD4+ TILs, so only 5000 cells were used for each analysis. Only two neoantigenspecific CD8+ TIL populations were detected (#13 and #20) ( Supplementary Fig. S13B ). However, the most dominant population (#13) was also observed in PBMCs during therapy response. Four additional neo-antigen populations were detected from PBMCs during early treatment when tumors were rapidly shrinking (Day 25), while only #13 and #14 were detected at a time point (Day 87) close to maximum therapeutic response (Supplementary Fig S13B) . All neoantigen-MHC library elements tested for patient #3 were calculated to exhibit strong binding (kd<50 nM). Similar to the case for patient #1, the correspondence between mutant mRNA reads and the detected T cell populations specific to these strong binding neoantigen-MHCs is weak ( Supplementary Fig S13B) .
Functional and Genetic Analysis of Identified Neoantigen-specific CD8+ T cell Populations
Exposure of antigen-specific CD8+ T cells to their cognate antigen/MHC complex should lead to T cell activation, and so an assay that probes for such activation can provide an independent validation of the population analysis methods reported here. To this end, we used ELISpot single cell assays of interferon-γ release, to confirm that the neoantigen-specific CD8+ populations from patient #1, day 41 PBMC were functionally activated following exposure to antigen (Fig 3D, Supplementary Table S9) . This assay provides a confirmation that the barcoded NP-NACS method is, in fact, working as described.
Barcoded T cells are still viable, and so we took advantage of this and designed a cell capture microchip with a low-density of cell traps (Supplementary Figure S14) . This design permits a single barcoded cell to be decoded using fluorescence imaging, and then punched from the device for single cell sequencing of the α and β chains of the TCR (Fig 4) . A CD8+ T cell from patient #1 was captured in a microfluidic trap (Supplementary Fig. S14 ) and barcoded to identify the neo-antigen identity (Fig. 4A ). RT-PCR was used on the retrieved cell to obtain the TCR α and β gene sequences, which were then cloned into a retroviral vector. Jurkat cells transduced to express that TCR were found to bind to the cognate neoantigen tetramer (Fig. 4B ).
Discussion
The rarity of individual populations of neoantigen-specific T cells in often-precious patient tumor tissues or blood can make them extremely challenging to detect and validate. Nevertheless, an in-depth knowledge of those populations can provide guidance for various vaccination (Gubin et al., 2014) Although the actual representation of those genotypes needs to be tested, the implication is that 30-50% of the CD8+ TILs within these patient tumors may well be neoantigen-specific. This number is significantly larger than would have been inferred using alternative analytic methods, but is consistent with a prior result in mice (Gubin et al., 2014) . Further, the neoantigen-specific T cell population numbers detected here are consistent with immune responses to tumor antigens that have been observed in healthy donors (Stronen et al., 2016) . In that work, PBMCs from the healthy donor were expanded in the presence of a library of Yadav, M., Jhunjhunwala, S., Phung, Q.T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T.K., Fritsche, J., Weinschenk, T., et al. (2014) . Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515, 572-576. For the middle plot, a tight gate was defined (all non-double fluorescent cells are strictly excluded). The bottom plot is for the NP-tetramer hemocytometry. Each plot includes a straight-line fit, the fitted slope and intercept (bottom right of each plot), and the R 2 fitting metric. All data was collected in triplicate. Some data points appear missing, but are actually just repeated observations of the same value, and so the points overlap. 
STAR Methods
Patients, treatment, and specimen collection
Patients with metastatic melanoma were selected for the current analysis by being HLA-A*02:01 positive, having an adequate baseline biopsy as well as an on-treatment biopsy, and exhibiting an objective tumor response while participating in a phase 1 trial of pembrolizumab. Patients #1 and #2 received single agent pembrolizumab intravenously 10 mg/kg every 3 weeks (10Q3W). Tumor responses were evaluated starting at 12 weeks, confirmed 4 weeks after first response, and imaged every 12 weeks thereafter. Response was characterized by both the Response Evaluation Criteria in Solid Tumors (RECIST) and the immune-related response criteria (irRC). Tumour biopsy and peripheral blood cell collection and analyses were approved by UCLA IRBs 11-001918 and 11-003066. Tumor biopsies from the patients analyzed were obtained at baseline and on therapy and were processed with one aliquot immediately fixed in formalin followed by paraffin embedding for pathological analyses, a second aliquot snap frozen by immediate immersion in liquid nitrogen for genetic analyses, and a third aliquot minced fresh under sterile condition followed by DNAse/collagenase digestion to create single cell suspensions (s.c.s) before cryopreservation in liquid nitrogen. Peripheral blood mononuclear cells (PBMCs) were prepared from fresh whole blood by FicollPaque density gradient centrifugation and cryopreserved.
TIL isolation and expansion
Tumor infiltrating lymphocytes were expanded from cryopreserved s.c.s using anti-CD3 antibody (OKT3, 50ng/mL, 48hr exposure) and IL-2 (300IU/mL) and re-cyropreserved at 5x10 6 cells/mL after 2-4 weeks. TILs were thawed and treated with DNAse for 45 min the morning of use, and stained with antibodies to CD4 (BV510, BioLegend, San Diego, CA) and CD8+ (BV605, BioLegend, San Diego, CA). Live (7AAD-negative) populations of CD4 and CD8+ single-positive cells were sorted using a FACS Cell Sorter (BD Biosciences, San Jose, CA).
Whole exome sequencing (WES), mutation calling and HLA-typing
Both DNA and RNA were extracted simultaneously from snap-frozen tumor biopsies (Qiagen AllPrep Kit). DNA from tumors and matched normal blood samples were sequenced at the UCLA Clinical Microarray Core. Paired-end 2x100bp sequencing was carried out on the HiSeq 2000 platform (Illumina, San Diego, CA) following exon capture using the Nimblegen SeqCap EZ Human Exome Library v3.0 (Roche), which targets 65 Mb of genome. Sequencing generated 6-10 billion reads per sample, with each targeted base covered by an average of 90-150 reads. Sequences were aligned to the UCSC hg19 human genome reference using BWA-mem algorithm (v0.7.9). Preprocessing followed the GATK Best Practices Workflow v3, including duplicate removal (Picard Tools), indel realignment, and base quality score recalibration. Somatic mutations were called with methods modified from 1 , using MuTect (v1.1.7) 2 , Varscan2 Somatic (v2.3.6) 3 , and the GATK-HaplotypeCaller (HC, v3.3). Only high-confidence mutations were retained, defined as those identified by at least two out of three programs. For the GATK-HC, somatic variants were determined using one-sided Fisher's Exact Test (P value cut-off ≤ 0.01) between tumor/normal pairs. Variants were annotated by Oncotator 4 , with non-synonymous mutations being those classified as Nonsense, Missense, Splice_Site, or Nonstop Mutations, as well as Frame_Shift, In_Frame, or Start_Codon altering insertions/deletions. HLA-typing was performed by ATHLATES from the whole exome sequencing data.
RNA sequencing
RNA sequencing was performed using the Illumina HiSeq 2500 platform on 100-bp paired-end libraries prepared using the IlluminaTruSeq RNA sample preparation kit per the manufacturer's instructions. Reads were mapped to hg19 using TopHat2 v2.0, 5 and were quantified and normalized using Cufflinks v2.2.1 6 program and CuffNorm to generate normalized expression tables by library size (fragments per kilobase of exon per million fragments mapped, FPKM) using the geometric normalization method. Mutationcontaining RNA reads were identified by a custom Python (v2.7.3) script utilizing the Biopython and pysam packages, and verified by visual inspection in the Integrated Genomics Viewer (IGV).
Peptide HLA binding prediction and neoantigen candidate identification
Peptide binding predictions to HLA-A02:01 were generated by netMHC3.4 7 for 9-mer and 10-mer peptides in a sliding window around each non-synonymous amino acid-altering mutation. (Peptide sequences were derived from Ensembl GRCh37 release 74.) Candidate peptides were binned by 1) those with mutationscontaining reads identified by RNA-seq, 2) those with RNA expression (FPKM > 0) but no identified mutated reads, and 3) all others without detectable RNA-seq expression. Peptides were ranked and sorted by HLA binding affinity within each bin.
Production of ssDNA-SAC conjugates
The ssDNA-SAC conjugate was produced following previous published protocol. 8 Briefly, SAC was first expressed from the pTSA-C plasmid containing the SAC gene (Addgene).
9 Before conjugation to DNA, SAC (1 mg/ml) was buffer exchanged to PBS containing Tris(2-Carboxyethyl) phosphine Hydrochloride (TCEP, 5 mM) using zeba desalting columns (Pierce). Then MHPH (3-N-Maleimido-6-hydraziniumpyridine hydrochloride, 100 mM, Solulink) in DMF was added to SAC at a molar excess of 300:1. In the meantime, SFB (succinimidyl 4-formylbenzoate, 100mM, Solulink) in DMF was added to 5'-amine modified ssDNA (500 µM) in a 40:1 molar ratio. After reacting at rt for 4 hours, MHPH-labeled SAC and SFB-labeled DNA were buffer exchanged to citrated (50 mM sodium citrate, 150 mM NaCl, pH 6.0), and then mixed in a 20:1 ratio of DNA to SAC to react at rt overnight. DNA-SAC conjugate was purified using the Superdex 200 gel filtration column (GE health) and concentrated with 10K MWCO ultracentrifuge filters (Millipore).
Human MHC class I neoantigen library construction
MHC library was generated using the UV-mediated peptide exchange method. 10 The photo-labile peptide KILGFVFJV and other neo-antigen peptides were synthesized with standard automated Fmoc-peptide synthesis methodology (J, (S)-3-(Fmoc-amino)-3-(2-nitrophenyl)propionic acid, is the photo-labile amino acid residue). Plasmids encoding human MHC class I heavy chain and human β2m containing bacterial strain were kind gifts from Ton N M Schumacher. MHC photo-labile protein was folded from MHC heavy chain inclusion body, β2m inclusion body and photo-labile peptide according to the previously published protocol 11 and then biotinylated using the BirA biotin ligase. Mixture of MHC photo-labile protein (0.5 µM) and neo-antigen peptide (50 µM) was exposed to 365 nm UV light for 1 hour to generate the MHC neo-antigen library.
NP MHC neo-antigen library construction
Streptavidin coated magnetic NPs (1 µm diameter, Invitrogen Dynabeads MyOne T1) were used. Each of these NPs can present up to 3x10 5 ssDNA oligomers on their surface, according to the manufacturer specifications. These NPs were mixed with biotin-DNA at 1:20 ratio to obtain NP-DNA. Excess DNA was removed by washing the magnetic NP for 3 times. In parallel, MHC neo-antigen library was added to ssDNA-SAC at 4:1 ratio to form the DNA-MHC tetramer. Equal amount (in terms of DNA ratio) of NP-DNA and DNA-MHC tetramer were hybridized at 37 o C for 30 min to generate the NP MHC neo-antigen library. An even simpler fashion of the library was constructed by incubating the Streptavidin magnetic NP with biotinylated MHC monomer at a ratio of 1:4 to 1:8 at rt for 30min. Excessive MHC monomer wash removed by washing the magnetic NP for 1-2X with PBS, 0.1% BSA. As obtained library has been used to analyze sample from Patient #3.
Cell-trapping microfluidic device fabrication
First, a master mold with cell traps (multiple traps or single traps) was prepared using the SU-8 2025 photoresist. Sylgard 184 (A:B = 10:1) mixture was then poured onto the mold, degassed and cured at 80 o C for 2 hours. In the meantime, a thin layer of PDMS was spun coated onto a glass slide at 2000 rpm/min and cured at 80 o C for 1 hour. The PDMS device and PDMS-coated glass were treated with O2 plasma for 1 min and bound together to get the final cell-trapping microfluidic device.
TIL pulldown and barcode
NP MHC neo-antigen library was added to CD 8+ human T cells for 15-30 min at rt. The NP-bound T cells were magnetically enriched and washed by PBS with 0.1% BSA to remove any non-specifically pulled T cells. The cells were then loaded into costar transwell polycarbonate membrane (5 µm pore) to remove free NPs. Then, the cells were loaded into the cell-trapping microfluidic device and sequentially barcoded. First, 3 different DNA-dyes (cy3, cy5 and Alex 488) were loaded to the device to hybridize with the DNA on the NP at 37 o C for 15 min. After a brief washing, fluorescent images were taken to obtain the first round barcode. Displacement DNAs were added to the device at 37 o C for 15 min to remove the first round DNA dyes. Similar procedures were employed to obtain the second and third round barcoding images.
CD8+ T cell pulldown from PBMC
CD8+ T cells from PBMC were sorted by FACS. CD8+ T cells were then stained with Calcein AM (a green-fluorescent live/dead stain, ThermoFisher) and incubated with each individual NP-NACS library at rt for 15-30 min. Neo-antigen specific cells were enriched by magnet pulldown. The non-captured T cells in the supernatant was collected for further incubation with other NP-NACS library element. The enriched T cells were washed by PBS once to remove any non-specific cell pulldown. Cells were then loaded into a cell hemocytometer. The whole area in the hemocytometer chip was imaged to obtain the total pulldown cell number. Healthy donor PBMC and/or PBMC from an unrelated male melanoma patient were used as control to obtain the background.
ELISPOT assay
8000 CD8+ T cells from PBMC (Day 41 from patient #1 or heathy donor, 100 µl in RPMI based media supplemented with 300 IU/ml IL-2) were stimulated with 0.1 µM final concentration of neo-antigen tetramers for 26 hours in a 37 o C CO2 incubator. Secreted human IFN-γ were detect by the ELISpot assay (R & D) following the manufacturer's suggested protocol, except with more stringent washing by increasing the repeated washing to 6 times in each washing step.
Sensitivity comparison of NP-barcoded NACS and Multicolor flow cytometry
Varying numbers ( For the NP-barcoded NACS comparison, similar samples of NY-ESO transduced Jurkat T cells (stained with Calcein AM, only live cell will be stained with green fluorescence) spiked into Jurkat T cells to obtain a total number of 10 000 cells were prepared and analyzed in triplicate. Cells were incubated with NY-ESO NP-NACS library element at rt for 15-30min. The magnetically labeled T cells were enriched using a magnet, washed with 100 µl PBS with 0.1% BSA, re-suspended in 10 µl PBS with 0.1% BSA, and loaded into a plastic hemocytometer (Incyto). The numbers of captured cells were counted using fluorescence microscopy by using the green fluorescent NY-ESO Jurkat T cells as signal.
Comparison of NP-barcoded NACS and multicolor flow cytometry for analysis of Patient #1
expanded TILs. In Figure 3C (top panel) of the main text we present an analysis of patient #1 expanded TILs using the NP-barcoded NACS approach. We analyzed a different vial of those similarly expanded TILs using multicolor flow cytometry method of Schumacher. For the flow analysis, we present, in Figure  S8 , multiple workups of the patient #1 TILs data set, in which we select the CD8++ live cells for workup using a tight or loose gating strategy, or we select all CD8+ live cells for workup, also using a tight or loose gating strategy. The top table (Fig. S8A) provides the dye labels that define each neoantigen-specific barcode. For example, a T cell that is dyed for both APC and PE will be identified as specific to neoantigen #1. In Fig. S8B A more promiscuous gating strategy is CD8+ live cells, tight gate (Fig. S8C) . In that analysis, 702 cells are detected as specific against neoantigen #12. This indicates that the neoantigen #12 specific T cell population resides exclusively in the CD8++ pool of cells. Only 3 other cells are found to stain with 2 colors, although a large number stain positive for only BV421. Note that for the most promiscuous selection (CD8+, loose gate) the numbers of doubly positive cells increases for a few populations. For the singly stained cells, BV421 and APC are over-represented. Thus, there may be some neoantigen specific populations within the CD8+ pool, but they do not express sufficient TCR to be detected as doubly stained.
Figures S9 are analogous workups of a data set from a healthy donor PBMC control, and Figure S10 provides the flow cytometry selection criteria for the patient #1 TILs analyzed by barcoded NP-NACS. In the main text we indicate that only T cells specific to neoantigen #12 are detected using the flow method.
Here we discuss that result in more detail. Figure S10 presents the gating strategy used to select cells for the barcoded NP-NACS analysis. This is analogous to CD8+ with a loose gate, but the barcoding and microscopy analysis permits additional restrictions to be added. Note that in this vial of expanded TILs, the CD8++ population is proportionately less than it is for Figures S9A-D (roughly 1/5 of the CD8+ cells versus 43% of the CD8+ cells that were analyzed by flow). This accounts for most of the discrepancy between those T cells identified as neoantigen specific. In other words, the neoantigen #12 specific cells identified by flow are CD8++. The fraction of CD8++ cells in the vial analyzed by flow is more than 2x higher than the corresponding fraction of those cells in the vial analyzed by NP-barcoded NACS.
Single cell TCR cloning
Neo-antigen specific T cells were trapped in the microfluidic device with single cell traps ( Supplementary  Fig. S13 ). The cells were then recovered by PDMS puncher. Brief sonication was applied to release the cell from the punched-out PDMS to cell lysis buffer (10mM Tris, pH=8, with 1U/µl RNAse inhibitor, Promega). Rearranged Vα and Vβ domain genes were cloned from single cells using a OneStep RT PCR kit (Qiagen) with multiplexed forward primers that bind TRAV and TRBV gene segments (Supplementary Tables S10  and S11 ) and reverse primers that bind the constant Cα (5'-GCCACAGCACTGTTGCTCTTGAAGTCC-3') and Cβ (5'-CCACCAGCTCAGCTCCACGTG-3') domain genes. cDNA products were used as templates in a second semi-nested amplification with a universal set of primers (alpha forward primer: 5'-TGGCCTGCTTTGTTTGCCGTGGTTACAGGAAGCCTCAGCA-3', alpha reverse primer: 5'-GCCACAGCACTGTTGCTCTTGAAGTCCATAG-3'; beta forward primer: 5'-CGGGCTCCTTTGCCTACCGTGCCTGCAGGAGGGCTCGGCA-3', beta reverse primer: 5'-CGTGCTGACCCCACTGTGCACCTCCTTCCCATTCACCCACCAGCTCAGCTCCACGTGGTC-3'). Vα and Vβ cDNA were sequenced and reamplified using single TRAV/TRBV forward primers to correct mispriming artifacts introduced through multiplexed PCR. Retroviral vectors were constructed for functional testing through PCR assembly. The Vα and Vβ domain genes were assembled with human growth hormone (HGH) signal peptides, constant regions of the TCRα and TCRβ chains, and a 2A ribosomal skipping sequence, then digested with restriction enzymes and ligated into a MSCV-based nonreplicative retroviral backbone.
To produce retrovirus, HEK-293T/17 cells were transfected via calcium phosphate precipitation with the TCR vector, a packaging vector encoding gag-pol, and a pseudotyping vector encoding RD114 envelope glycoprotein. Media was replaced 24 hours following transfection and viral supernatant was collected 48 hours following transfection. An equal volume of viral supernatant was added to Jurkat T cells in RPMIbased medium (final density: 0.5 x 10 6 cells/mL) and polybrene was added to a final concentration of 5 μg/mL. Cells were spinfected at 1350xg for 90 minutes at 30 °C, and then incubated with virus overnight at 37 °C, 5% CO2. Half of the media was replaced 24 hours following infection and cells were assayed for TCR specificity 48 hours following infection via flow cytometry using cognate fluorescent peptide-MHC tetramers. Fig. S1 . Sensitivity comparison of NP-NACS and FACS methods. A. FACS plots for loose gate and tight gate controls. The loose gate is determined by visual separation of double-fluorescent positive Jurkat T cells from double-fluorescent negative Jurkat T cells (upper left). The tight gate is set to eliminate any possible leak of double-fluorescent positive signals from non-stained Jurkat T cells, as well as PE-NY-ESO or APC-NY-ESO single stain controls (lower left). B. Typical image from the NP-NACS capture, as recorded using a hemocytometry microchip. The single T cell shown was captured with a magnet, along with unbound tetramer-functionalized magnetic NPs. The captured cell appears black in the bright field image, because it is covered by barcoded magnetic NPs. It appears green in the fluorescent image due to the live cell/dead cell stain calcein AM (Life Tech) (right). Scale bar is 50 µm. C. Plot of number of NY-ESO Jurkat T cells detected by NP-NACS capture, and by FACS, with both loose gate and tight gate definitions. For the measurements, a known number, between 0 and 1000, of NY-ESO TCR-specific Jurkat T cells were spiked into a background of non-transfected Jurkat cells, keeping the total cell count at 10,000. Each plot provides linear regression fits to the data (solid curve) over the full spiking range. The fitted slope and intercept, and statistical uncertainties (given as standard error) are provided on each plot. The x-axis is the numbers of cells spiked, while the y-axis is the numbers of cells detected. All measurements are in triplicate for each spiking condition. S4 . Capture percentage of neoantigen-specific CD8+ cells T for patient #1 using two independent cell captures with NP-barcoded NACS library 1-27. Non-selective capture is estimated to be around 0.5%, as gauged by the relative numbers of CD4+ T cells that were captured using the same method. The two independent captures were carried out more than one week apart. Fig. S5 . Neoantigen population detected from expanded TILs from the tumor of patient #1. For each run, approximately 10,000 CD8+ TILs were analyzed per run, and isolated within the cell capture chambers of the microfluidic chip for fluorescence-based readouts of the attached NP-barcodes. Capture efficiency within the microfluidic chip was about 10%. Runs #1 and #2 utilized the same 27-element NP-barcoded NACS library, corresponding to the top-ranked 27 putative neoantigens. All populations shown for runs #1 and #2 were detected in both runs, excepting neoantigen #5, which was detected in 4 clean reads only in run #2. Run #3 utilized a NP-barcoded NACS library designed to capture CD8+ T cells specific to neoantigens rank ordered 28-50.
Sensitive, non-destructive detection of neoantigen-specific T cell populations from tumors and blood
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. Fig. S6 . Results of control experiments in which the NP-barcoded NACS library designed for patient #1 was utilized to capture CD8+ PBMCs from a different melanoma cancer patient (blue) and from a healthy donor (orange). A. Average numbers of pulled-down T cells, per library element, from healthy donor PBMC and PBMC from an unrelated melanoma patient, on the same clinical trial as patient #1. Data was presented as mean ± standard deviation. B. The numerical labels on the x-axis corresponds to the rank-order of the putative neoantigens. The data has been sorted according to frequency of detection for the melanoma patient, so as to illustrate that there is no correlation between these two controls. A correlation would likely indicate capture by non-selective library elements. The noise threshold was set at the average plus two standard deviations. Fig. S7 . TIL analysis of Patient #2 over the course of response to anti-PD-1 therapy, using the NP-barcoded NACS library to enumerate neoantigen-specific CD8+ T cell populations. A. The timeline of the lesion size of subcarinal lymph node, supraclavicular lymph node, and neck in Patient #2. Day 0 corresponds to the start of anti-PD-1 therapy. A baseline tumor biopsy (indicated by the purple arrow) was collected for genomic and transcriptomic analysis at day -11. Black dots represent CT-scan measurement dates, while the green arrow corresponds to the time point of analysis. B. Analysis of patient #2 TILs for neoantigenspecific CD8+ T cell populations using a NP-barcode NACS library based upon the top 28 putative neoantigens predicted for patient #2, plus the MART-1 tumor antigen. Only T cell populations detected at more than 5 cells per 3000 TILs are considered statistically significant. The bottom graph shows the mRNA copies measured for the mutated proteins from which the neoantigens derive. The top table presents which neoantigen library elements were dyed with which fluorophores. For example, neoantigen #9 is dyed with QD605 and PE. The lower 4 tables list the numbers of cells that were analyzed (indicated by the number under CD8), and then the numbers of cells that detected as staining positive for a single fluorphore, as well as those that stained positive for two and only two fluorphores. Four different gating conditions are provided. The terms 'tight gate' and 'loose gate' refer to the gating levels set on the 2-color detected cells, not on the CD8 selection. The CD8 selection was either done for CD8+ (right two tables) or the CD8++ subset of the CD8+ cells (left two tables). 
Fig. S10. CD8 + T cells used in the NP-barcoded NACS analysis. TILs tested were expanded longterm (37 days) in-vitro following anti-CD3 (OKT3) + IL-2 stimulation. Chronic stimulation can lead to CD8 and TCR downregulation 1 , which we observed as CD8 ++ and CD8 + populations with a 4-fold difference in median fluorescence intensity. S12 . Results of control experiments in which the NP-barcoded NACS library designed for patient #3 was utilized to capture CD8+ PBMCs from a healthy donor. Average pulled-down T cells from healthy donor PBMC was 0.9 ± 1.1 (mean ± standard deviation). The noise threshold was set at average plus two standard deviations. Fig. S13 . TIL and PBMC analysis of Patient #3 over the course of response to anti-PD-1 therapy, using the barcoded NP-NACS library to enumerate neoantigen-specific CD8+ T cell populations. A. The timeline of the lesion size of chest, lung, liver and intra-abdominal in Patient #3. Day 0 corresponds to the start of anti-PD-1 therapy. A baseline tumor biopsy (indicated by the purple arrow) was collected for genomic and transcriptomic analysis at day -29. Black dots represent CT-scan measurement dates, while the arrows correspond to the time points of analysis, and are color coded for the bar graphs in part B. B. Neoantigenspecific T cell populations detected from expanded TILs collected from baseline (top graph) and PBMCs over the course of the therapy (middle two graphs), along with mutation-containing mRNA read counts for the mutant proteins (bottom graph) from the baseline RNA-seq. The horizontal dashed lines in the TIL and PBMC analysis graphs represent the signal threshold above which the identification of a T cell population is statistically significant, which is determined in Fig. S7 . The vertical gray dashed lines indicate T cell populations detected across the different time points and patient materials, and their correlation with RNA transcripts reads. Conditional antigen (MHC-J) was used as an internal control. 5'-TACAGGAAGCCTCAGCA GGACAAAGCCTTGAGCAGCCCTC-3' TRAV1-2*01 5'-TACAGGAAGCCTCAGCA GGACAAAACATTGACCAGCCCACTG-3' TRAV2*01 5'-TACAGGAAGCCTCAGCA AAGGACCAAGTGTTTCAGCCTTCCAC-3' TRAV3*01 5'-TACAGGAAGCCTCAGCA GCTCAGTCAGTGGCTCAGCCGGA-3' TRAV4*01 5'-TACAGGAAGCCTCAGCA CTTGCTAAGACCACCCAGCCCATC-3' TRAV5*01 5'-TACAGGAAGCCTCAGCA GGAGAGGATGTGGAGCAGAGTCTTTTCC-3' TRAV6*01 5'-TACAGGAAGCCTCAGCA AGCCAAAAGATAGAACAGAATTCCGAGGC-3' TRAV6*03 5'-TACAGGAAGCCTCAGCA GAGGCCCTGAACATTCAGGAGGG-3' TRAV7*01 5'-TACAGGAAGCCTCAGCA GAAAACCAGGTGGAGCACAGCCC-3' TRAV8-1*01 5'-TACAGGAAGCCTCAGCA GCCCAGTCTGTGAGCCAGCATAACC-3' TRAV8-2*01 5'-TACAGGAAGCCTCAGCA GCCCAGTCGGTGACCCAGCTTG-3' TRAV8-2*02 5'-TACAGGAAGCCTCAGCA GCCCAGTCGGTGACCCAGCTTAG-3' TRAV8-3*01 5'-TACAGGAAGCCTCAGCA GCCCAGTCAGTGACCCAGCCTG-3' TRAV8-4*06 5'-TACAGGAAGCCTCAGCA CTCTTCTGGTATGTGCAATACCCCAACC-3' TRAV8-4*07 5'-TACAGGAAGCCTCAGCA GTTGAACCATATCTCTTCTGGTATGTGCAATACC-3' TRAV8-6*01 5'-TACAGGAAGCCTCAGCA GCCCAGTCTGTGACCCAGCTTGAC-3' TRAV8-7*01 5'-TACAGGAAGCCTCAGCA ACCCAGTCGGTGACCCAGCTTG-3' TRAV9-1*01 5'-TACAGGAAGCCTCAGCA GGAGATTCAGTGGTCCAGACAGAAGGC-3' TRAV9-2*01 5'-TACAGGAAGCCTCAGCA GGAAATTCAGTGACCCAGATGGAAGG-3' TRAV9-2*02 5'-TACAGGAAGCCTCAGCA GGAGATTCAGTGACCCAGATGGAAGG-3' TRAV10*01 5'-TACAGGAAGCCTCAGCA AAAAACCAAGTGGAGCAGAGTCCTCAGTC-3' TRAV11*01 5'-TACAGGAAGCCTCAGCA CTACATACACTGGAGCAGAGTCCTTCATTCC-3' TRAV12-1*01 5'-TACAGGAAGCCTCAGCA CGGAAGGAGGTGGAGCAGGATCC-3' TRAV12-2*01 5'-TACAGGAAGCCTCAGCA CAGAAGGAGGTGGAGCAGAATTCTGG-3' TRAV12-2*03 5'-TACAGGAAGCCTCAGCA GGACCCCTCAGTGTTCCAGAGGG-3' TRAV12-3*01 5'-TACAGGAAGCCTCAGCA CAGAAGGAGGTGGAGCAGGATCCTG-3' TRAV13-1*02 5'-TACAGGAAGCCTCAGCA GGAGAGAATGTGGAGCAGCATCCTTC-3' TRAV13-2*01 5'-TACAGGAAGCCTCAGCA GGAGAGAGTGTGGGGCTGCATCTTC-3' TRAV14/DV4*01 5'-TACAGGAAGCCTCAGCA GCCCAGAAGATAACTCAAACCCAACCAG-3' TRAV14/DV4*04 5'-TACAGGAAGCCTCAGCA CAGAAGATAACTCAAACCCAACCAGGAATG-3' TRAV16*01 5'-TACAGGAAGCCTCAGCA GCCCAGAGAGTGACTCAGCCCGA-3' TRAV17*01 5'-TACAGGAAGCCTCAGCA AGTCAACAGGGAGAAGAGGATCCTCAGG-3' TRAV18*01 5'-TACAGGAAGCCTCAGCA GGAGACTCGGTTACCCAGACAGAAGG-3' TRAV19*01 5'-TACAGGAAGCCTCAGCA GCTCAGAAGGTAACTCAAGCGCAGACTG-3' TRAV20*01 5'-TACAGGAAGCCTCAGCA GAAGACCAGGTGACGCAGAGTCCC-3' TRAV21*01 5'-TACAGGAAGCCTCAGCA AAACAGGAGGTGACGCAGATTCCTGC-3' TRAV22*01 5'-TACAGGAAGCCTCAGCA GGAATACAAGTGGAGCAGAGTCCTCCAG-3' TRAV23/DV6*01 5'-TACAGGAAGCCTCAGCA CAGCAGCAGGTGAAACAAAGTCCTCA-3' TRAV23/DV6*04 5'-TACAGGAAGCCTCAGCA CAGCAGGTGAAACAAAGTCCTCAATCTTTG-3' TRAV24*01 5'-TACAGGAAGCCTCAGCA ATACTGAACGTGGAACAAAGTCCTCAGTCAC-3' TRAV25*01 5'-TACAGGAAGCCTCAGCA GGACAACAGGTAATGCAAATTCCTCAGTACC-3' TRAV26-1*01 5'-TACAGGAAGCCTCAGCA GATGCTAAGACCACCCAGCCCCC-3' TRAV26-1*02 5'-TACAGGAAGCCTCAGCA GATGCTAAGACCACCCAGCCCACC-3' TRAV26-2*01 5'-TACAGGAAGCCTCAGCA GATGCTAAGACCACACAGCCAAATTCAATG-3' TRAV27*01 5'-TACAGGAAGCCTCAGCA ACCCAGCTGCTGGAGCAGAGCC-3' TRAV29/DV5*01 5'-TACAGGAAGCCTCAGCA GACCAGCAAGTTAAGCAAAATTCACCATC-3' TRAV30*01 5'-TACAGGAAGCCTCAGCA CAACAACCAGTGCAGAGTCCTCAAGC-3' TRAV34*01 5'-TACAGGAAGCCTCAGCA AGCCAAGAACTGGAGCAGAGTCCTCAG-3' TRAV35*01 5'-TACAGGAAGCCTCAGCA GGTCAACAGCTGAATCAGAGTCCTCAATC-3' TRAV36/DV7*01 5'-TACAGGAAGCCTCAGCA GAAGACAAGGTGGTACAAAGCCCTCTATCTC-3' TRAV36/DV7*02 5'-TACAGGAAGCCTCAGCA GAAGACAAGGTGGTACAAAGCCCTCAATC-3' TRAV38-1*01 5'-TACAGGAAGCCTCAGCA GCCCAGACAGTCACTCAGTCTCAACCAG-3' TRAV38-1*04 5'-TACAGGAAGCCTCAGCA GCCCAGACAGTCACTCAGTCCCAGC-3' TRAV38-2/DV8*01 5'-TACAGGAAGCCTCAGCA GCTCAGACAGTCACTCAGTCTCAACCAGAG-3' TRAV39*01 5'-TACAGGAAGCCTCAGCA GAGCTGAAAGTGGAACAAAACCCTCTGTTC-3' TRAV40*01 5'-TACAGGAAGCCTCAGCA AGCAATTCAGTCAAGCAGACGGGC-3' TRAV41*01 5'-TACAGGAAGCCTCAGCA AAAAATGAAGTGGAGCAGAGTCCTCAGAAC-3'
Supplementary Table S11 single cell TCRβ cloning primers.
Vβ-gene-specific primers for cloning TCRα genes TRBV gene Signal peptide sequence TRBV gene-specific sequence TRBV1*01 5'-CAGGAGGGCTCGGCA GATACTGGAATTACCCAGACACCAAAATACCTG-3' TRBV2*01 5'-CAGGAGGGCTCGGCA GAACCTGAAGTCACCCAGACTCCCAG-3' TRBV3-1*01 5'-CAGGAGGGCTCGGCA GACACAGCTGTTTCCCAGACTCCAAAATAC-3' TRBV3-2*01 5'-CAGGAGGGCTCGGCA GACACAGCCGTTTCCCAGACTCCA-3' TRBV4-1*01 5'-CAGGAGGGCTCGGCA GACACTGAAGTTACCCAGACACCAAAACAC-3' TRBV4-1*02 5'-CAGGAGGGCTCGGCA CACCTGGTCATGGGAATGACAAATAAGAAG-3' TRBV4-2*01 5'-CAGGAGGGCTCGGCA GAAACGGGAGTTACGCAGACACCAAG-3' TRBV4-3*04
5'-CAGGAGGGCTCGGCA AAGAAGTCTTTGAAATGTGAACAACATCTGGG-3' TRBV5-1*01 5'-CAGGAGGGCTCGGCA AAGGCTGGAGTCACTCAAACTCCAAGATATC-3' TRBV5-1*02 5'-CAGGAGGGCTCGGCA AGGGCTGGGGTCACTCAAACTCC-3' TRBV5-3*01 5'-CAGGAGGGCTCGGCA GAGGCTGGAGTCACCCAAAGTCCC-3' TRBV5-4*01 5'-CAGGAGGGCTCGGCA GAGACTGGAGTCACCCAAAGTCCCAC-3' TRBV5-4*03 5'-CAGGAGGGCTCGGCA CAGCAAGTGACACTGAGATGCTCTTCTCAG-3' TRBV5-4*04 5'-CAGGAGGGCTCGGCA ACTGTGTCCTGGTACCAACAGGCCCT-3' TRBV5-5*01 5'-CAGGAGGGCTCGGCA GACGCTGGAGTCACCCAAAGTCC-3' TRBV5-8*01
5'-CAGGAGGGCTCGGCA GAGGCTGGAGTCACACAAAGTCCCAC-3' TRBV5-8*02
5'-CAGGAGGGCTCGGCA AGGACAGCAAGCGACTCTGAGATGC-3' TRBV6-1*01 5'-CAGGAGGGCTCGGCA AATGCTGGTGTCACTCAGACCCCA-3' TRBV6-4*01 5'-CAGGAGGGCTCGGCA ATTGCTGGGATCACCCAGGCAC-3' TRBV6-4*02 5'-CAGGAGGGCTCGGCA ACTGCTGGGATCACCCAGGCAC-3' TRBV7-1*01 5'-CAGGAGGGCTCGGCA GGTGCTGGAGTCTCCCAGTCCCTG-3' TRBV7-2*01 5'-CAGGAGGGCTCGGCA GGAGCTGGAGTCTCCCAGTCCCC-3' TRBV7-2*04 5'-CAGGAGGGCTCGGCA GGAGCTGGAGTTTCCCAGTCCCC-3' TRBV7-3*01 5'-CAGGAGGGCTCGGCA GGTGCTGGAGTCTCCCAGACCC-3' TRBV7-3*05 5'-CAGGAGGGCTCGGCA TGGGAGCTCAGGTGTGATCCAATTTC-3' TRBV7-4*01 5'-CAGGAGGGCTCGGCA GGTGCTGGAGTCTCCCAGTCCC-3' TRBV7-6*01 5'-CAGGAGGGCTCGGCA GGTGCTGGAGTCTCCCAGTCTCCC-3' TRBV7-9*01 5'-CAGGAGGGCTCGGCA GATACTGGAGTCTCCCAGAACCCCAG-3' TRBV7-9*03 5'-CAGGAGGGCTCGGCA GATACTGGAGTCTCCCAGGACCCCAG-3' TRBV7-9*04 5'-CAGGAGGGCTCGGCA ATATCTGGAGTCTCCCACAACCCCAGAC-3' TRBV7-9*07 5'-CAGGAGGGCTCGGCA CACAACCGCCTTTATTGGTACCGACAG-3' TRBV9*01 5'-CAGGAGGGCTCGGCA GATTCTGGAGTCACACAAACCCCAAAGC-3' TRBV10-1*01 5'-CAGGAGGGCTCGGCA GATGCTGAAATCACCCAGAGCCCAAG-3' TRBV10-2*01 5'-CAGGAGGGCTCGGCA GATGCTGGAATCACCCAGAGCCCA-3' TRBV10-2*02 5'-CAGGAGGGCTCGGCA AAGGCAGGTGACCTTGATGTGTCACC-3' TRBV11-1*01 5'-CAGGAGGGCTCGGCA GAAGCTGAAGTTGCCCAGTCCCC-3' TRBV11-2*01 5'-CAGGAGGGCTCGGCA GAAGCTGGAGTTGCCCAGTCTCCCAG-3' TRBV11-3*01 5'-CAGGAGGGCTCGGCA GAAGCTGGAGTGGTTCAGTCTCCCAGA-3' TRBV11-3*03 5'-CAGGAGGGCTCGGCA GGTCTCCCAGATATAAGATTATAGAGAAGAAACAGC-3' TRBV12-1*01 5'-CAGGAGGGCTCGGCA GATGCTGGTGTTATCCAGTCACCCAGG-3' TRBV12-2*01 5'-CAGGAGGGCTCGGCA GATGCTGGCATTATCCAGTCACCCAAG-3' TRBV12-3*01 5'-CAGGAGGGCTCGGCA GATGCTGGAGTTATCCAGTCACCCC-3' TRBV12-5*01 5'-CAGGAGGGCTCGGCA GATGCTAGAGTCACCCAGACACCAAGG-3' TRBV13*01 5'-CAGGAGGGCTCGGCA GCTGCTGGAGTCATCCAGTCCCC-3' TRBV14*01 5'-CAGGAGGGCTCGGCA GAAGCTGGAGTTACTCAGTTCCCCAGC-3' TRBV15*01 5'-CAGGAGGGCTCGGCA GATGCCATGGTCATCCAGAACCCAAG-3' TRBV16*01 5'-CAGGAGGGCTCGGCA GGTGAAGAAGTCGCCCAGACTCCA-3' TRBV17*01 5'-CAGGAGGGCTCGGCA GAGCCTGGAGTCAGCCAGACCC-3' TRBV18*01 5'-CAGGAGGGCTCGGCA AATGCCGGCGTCATGCAGAAC-3' TRBV19*01 5'-CAGGAGGGCTCGGCA GATGGTGGAATCACTCAGTCCCCAAAG-3' TRBV20-1*01 5'-CAGGAGGGCTCGGCA GGTGCTGTCGTCTCTCAACATCCGAG-3' TRBV20/OR9-2*01 5'-CAGGAGGGCTCGGCA AGTGCTGTCGTCTCTCAACATCCGAG-3' TRBV21-1*01 5'-CAGGAGGGCTCGGCA GACACCAAGGTCACCCAGAGACCTAGAC-3' TRBV21/OR9-2*01 5'-CAGGAGGGCTCGGCA GACACCAAGGTCACCCAGAGACCTAGATTTC-3' TRBV23-1*01 5'-CAGGAGGGCTCGGCA CATGCCAAAGTCACACAGACTCCAGG-3' TRBV24-1*01 5'-CAGGAGGGCTCGGCA GATGCTGATGTTACCCAGACCCCAAG-3' TRBV25-1*01 5'-CAGGAGGGCTCGGCA GAAGCTGACATCTACCAGACCCCAAGATAC-3' TRBV26*01 5'-CAGGAGGGCTCGGCA GATGCTGTAGTTACACAATTCCCAAGACACAG-3' TRBV26/OR9-2*01 5'-CAGGAGGGCTCGGCA GATGCTGTAGTTACACAATTCTCAAGACACAGAATC-3' TRBV27*01 5'-CAGGAGGGCTCGGCA GAAGCCCAAGTGACCCAGAACCC-3' TRBV28*01 5'-CAGGAGGGCTCGGCA GATGTGAAAGTAACCCAGAGCTCGAGATATC-3' TRBV29-1*01 5'-CAGGAGGGCTCGGCA AGTGCTGTCATCTCTCAAAAGCCAAGC-3' TRBV29-1*03 5'-CAGGAGGGCTCGGCA ACGATCCAGTGTCAAGTCGATAGCCAAG-3' TRBV30*01 5'-CAGGAGGGCTCGGCA TCTCAGACTATTCATCAATGGCCAGCG-3' TRBV30*04 5'-CAGGAGGGCTCGGCA ACTATTCATCAATGGCCAGCGACCC-3'
